

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Attorney Docket No.: 54704.8036.US03 (UMP-0072)
Inventors: John Langenfeld
Serial No.: 10/692,824
Filing Date: October 23, 2003
Examiner: Stephen L. Rawlings
Customer No.: 46046
Group Art Unit: 1642
Confirmation No.: 1322
Title: Bone Morphogenetic Protein-2 in the
Treatment and Diagnosis of Cancer

Electronically Submitted via EFS-Web

Date: July 12, 2006

I hereby certify that this paper is being electronically
submitted on the date indicated above to the
Commissioner for Patents, U.S. Patent &
Trademark Office (Fee Amendment).

By Jane Massey Licata

Typed Name: Jane Massey Licata, Reg. No. 32,257

Commissioner for Patents
U.S. Patent & Trademark Office
(Fee Amendment)

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Pursuant to 37 C.F.R. §1.56 and in accordance with
37 C.F.R. §§1.97-1.98, information relating to the above-
identified application is hereby disclosed. Inclusion of
information in this statement is not to be construed as an
admission that this information is material as that term is
defined in 37 C.F.R. §1.56(b).

() In accordance with §1.97(b), since this Information
Disclosure Statement is being filed either within three

months of the filing date of the above-identified application, within three months of the date of entry into the national stage of the above identified application as set forth in §1.491, or before the mailing date of a first Office Action on the merits of the above-identified application, no additional fee is required.

- () In accordance with §1.97(c), this Information Disclosure Statement is being filed after the period set forth in §1.97(b) above but before the mailing date of either a Final Action under §1.113 or a Notice of Allowance under §1.311, therefore:

() Certification in Accordance with §1.97(e) is attached hereto; or

() Authorization to charge Deposit Account No. 50-1619 the fee of \$180.00 as set forth in §1.17(p) is provided.

- (XX) In accordance with §1.97(d), this Information Disclosure Statement is being filed after the mailing date of either a Final Action under §1.113 or a Notice of Allowance under §1.311 but before the payment of the Issue Fee, therefore included is a Petition Requesting Consideration of the Information Disclosure Statement; and the fee of \$130.00 as set forth in §1.17(I)(1).

- (XX) Copies of each of the references listed on the attached Form PTO-1449 (modified) are enclosed herewith.

- () In accordance with §1.98(d), copies of some or all of the references listed on the attached Form PTO-1449 (modified) are not enclosed herewith because they were previously submitted to the U.S. Patent and Trademark Office in prior application Serial No. _____,


filed _____, for which a claim for priority under 35 U.S.C. §120 has been made in the instant application.

Please charge any deficiency or credit any overpayment to Deposit Account No. 50-1619. This form is submitted in duplicate.

() The relevance of the listed references in a foreign language is as stated in the specification at pages @@.

(XX) Reference 1 (EA) is in a Foreign language and an English Abstract is provided and Reference 2 (EB) is in the English language.

Respectfully submitted,



Jane Massey Licata
Registration No. 32,257

Date: July 12, 2006

Licata & Tyrrell P.C.
66 E. Main Street
Marlton, New Jersey 08053

(856) 810-1515